First ever national HTA relying on an EU JCA results in rejection of product for reimbursement

The national Health Technology Assessment (“HTA”) by the Irish National Centre for Pharmacoeconomics (“NCPE”) of Novartis’ Itvisma was the first HTA in which, according to the NCPE, an EU Joint Clinical Assessment